Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
TauRx Therapeutics Ltd, a clinical-stage biopharmaceutical company developing a novel treatment for Alzheimer's disease, has expanded its international clinical trials by adding new research centers across the U.S. The addition of 35 clinical research centers means that more patients suffering from mild or moderate Alzheimer's, and their caregivers, will have an opportunity to see if they qualify for participation in TauRx's Alzheimer's clinical trials. Professor Claude M. Wischik, MD, TauRx's Co-founder and Chairman, said, "TauRx's treatment, LMTX(TM), being evaluated in Phase 3 clinical trials for Alzheimer's, will represent a breakthrough in dementia treatment if, as we hope to demonstrate, it slows and even halts the progression of the disease, as our earlier studies have shown."
"This compound is potentially a disease-modifying approach to treating Alzheimer's, targeting the tangles of tau protein that develop in the brain which are clearly linked to the progression of dementia," said Professor Wischik. "We are pleased to expand the number of research centers conducting our clinical trial to permit more people across the U.S. to access our study." Importantly, added Wischik, "Only by participating in clinical studies such as ours, can we collectively - in partnership with those living with Alzheimer's - help advance the essential research that can result in the development of new medicines for this terminal medical condition."
The main purpose of TauRx's Phase 3 clinical research studies is to evaluate the effects of LMTX(TM), a second generation tau aggregation inhibitor, on slowing and/or halting the progression of Alzheimer's disease. There is currently no cure for Alzheimer's, nor are there any current treatments that halt the progression of memory loss.
The expansion of study centers in the U.S. means that eligible patients in areas such as Bennington, Vermont; Farmington Hills, Michigan; Waukesha, Wisconsin; and Creve Coeur, Missouri can also participate in the studies.
With 5.2 million Americans living with Alzheimer's, chances are you probably know someone who is affected by Alzheimer's. You may have friends or family members who are living with Alzheimer's, which is currently the 6(th) leading cause of death in the U.S. Patients and caregivers who are interested in learning more about potentially participating in TauRx's Alzheimer's clinical trials can visit http://www.AlzheimersPressRelease.com or call 1-855-786-7259.
Alzheimer's disease is one of the most important health challenges worldwide, and the most common cause of dementia. According to the Geneva-based World Health Organization and Alzheimer's Disease International, global dementia cases are expected to triple by 2050 to an estimated 135 million people. One of the hallmark signs of Alzheimer's, tau tangles, are present in the same regions of the brain where neuronal degeneration and loss of neuronal cells eventually occur. These changes first appear 20-30 years before the disease becomes clinically evident.
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our Alzheimer's / Dementia category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
Ltd, TauRx Therapeutics. "TauRx expands alzheimer's clinical trials in the United States." Medical News Today. MediLexicon, Intl., 8 Jan. 2014. Web.
7 Mar. 2014. <http://www.medicalnewstoday.com/releases/270886>
Ltd, T. (2014, January 8). "TauRx expands alzheimer's clinical trials in the United States." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/270886.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2014 All rights reserved. MNT (logo) is the registered trade mark of MediLexicon International Limited.